Cyano temozolomide | CAS:114601-31-9

We serve Cyano temozolomide CAS:114601-31-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
 Cyano temozolomide

Synonyms:
7-hydroxy-1-cyanonaphthalene
8-Cyano-2-naphthol
1-Naphthalenecarbonitrile,7-hydroxy
7-Hydroxy-1-naphthonitrile
cyanotemozolomide
 
Molecular Formula: C6H4N6O
Molecular Weight: 176.13600

Density: 1.743 g/cm3
Boiling point: 415.285ºC at 760 mmHg
Melting point: 48-50ºC
Flash point: 204.958ºC

Items of Analysis Standard of Analysis Test Results
Appearance Pink or light yellow crystal Conform
Loss on drying ≤1.0% 0.19%
Total impurities ≤1.0% 0.04%
Purity(HPLC) ≥99.0% 99.96%
CONCLUSION Conforms to Factory Standard
 

 



Contact us for information like Cyano temozolomide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cyanotemozolomide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-Hydroxy-1-naphthonitrile Use and application,Cyano temozolomide technical grade,usp/ep/jp grade.


Related News: Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.(S)-2-((S)-12-Azido-tridecyl)-pyrrolidine-1-carboxylic acid tert-butyl ester manufacturer At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.3-(4-((1-benzyl-1H-indol-5-yl)amino)quinazolin-6-yl)-1-(pyrrolidin-2-yl)prop-2-yn-1-ol supplier At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.1-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indene vendor Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.